Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT.

PubWeight™: 0.76^‹?›

🔗 View Article (PMC 4562539)

Published in Haematologica on July 04, 2014

Authors

Yves Chalandon¹, Jakob R Passweg², Cesare Guglielmi³, Simona Iacobelli⁴, Jane Apperley⁵, Nicolaas P M Schaap⁶, Jürgen Finke⁷, Marie Robin⁸, Roberta Fedele⁹, Dominique Bron¹⁰, Ibrahim Yakoub-Agha¹¹, Anja van Biezen¹², Theo de Witte⁶, Nicolaus Kröger¹³, Eduardo Olavarria¹⁴, Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

Author Affiliations

1: Division of Hematology, Department of Medical Specialties, University Hospital, Geneva, Switzerland yves.chalandon@hcuge.ch.
2: Hematology Division, University Hospital, Basel, Switzerland.
3: Universita La Sapienza, II Facolta di Medicina, U.O.C Ematologia A.O.S. Andrea, Rome, Italy.
4: Centro di Biostatistica e Bioinformatica, Università "Tor Vergata", Rome, Italy.
5: Imperial College, Department of Haematology, Hammersmith Hospital, London, UK.
6: Radboud University - Nijmegen Medical Center, Department of Hematology, Nijmegen, The Netherlands.
7: Dept. of Medicine-Hematology, Oncology, University of Freiburg, Freiburg, Germany.
8: Dept. of Hematology-BMT, Hopital St. Louis, Paris, France.
9: Centro Unico Regionale Trapianti, Azienda Ospedaliera, Reggio Calabria, Italy.
10: Experimental Hematology, Institut Jules Bordet, Brussels, Belgium.
11: UAM allo-CSH, CHRU Hopital Huriez, Lille, France.
12: Chronic Malignancies WP Registry, Dept. Medical Statistics and Bioinformatics, Leiden, The Netherlands.
13: University Hospital Hamburg, Hamburg, Germany.
14: Complejo Hospitalario de Navarra, Pamplona, Spain.

Articles citing this ↘

Novel therapeutic options in Acute Myeloid Leukemia. Leuk Res Rep (2016) 0.75

Optimizing peripheral blood stem cells transplantation outcome through amend relapse and graft failure: a review of current literature. Exp Hematol Oncol (2017) 0.75

Articles cited by this ↗

Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood (1995) 5.34

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol (1997) 4.51

Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood (1990) 3.50

Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood (1995) 2.59

Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood (2000) 1.84

Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy. Leukemia (2007) 1.53

Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia (2003) 1.47

Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood (2000) 1.27

Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol (2005) 1.24

Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood (1993) 1.19

Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMT. Bone Marrow Transplant (2009) 1.07

Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet (1984) 1.06

Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol (1993) 1.06

Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood (2007) 1.03

Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood (2002) 0.99

Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood (1994) 0.99

Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. Biol Blood Marrow Transplant (1999) 0.96

Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. Exp Hematol (1999) 0.95

Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy. Hematol Oncol Clin North Am (1999) 0.85

Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood (1992) 0.84

Articles by these authors ⇆

Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease? Biol Blood Marrow Transplant (2015) 0.78

Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study. Ann Hematol (2016) 0.75